JP2013523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523676A5
JP2013523676A5 JP2013501779A JP2013501779A JP2013523676A5 JP 2013523676 A5 JP2013523676 A5 JP 2013523676A5 JP 2013501779 A JP2013501779 A JP 2013501779A JP 2013501779 A JP2013501779 A JP 2013501779A JP 2013523676 A5 JP2013523676 A5 JP 2013523676A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inulin
solvent
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501779A
Other languages
English (en)
Japanese (ja)
Other versions
JP5907945B2 (ja
JP2013523676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/054698 external-priority patent/WO2011120903A2/en
Publication of JP2013523676A publication Critical patent/JP2013523676A/ja
Publication of JP2013523676A5 publication Critical patent/JP2013523676A5/ja
Application granted granted Critical
Publication of JP5907945B2 publication Critical patent/JP5907945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501779A 2010-03-29 2011-03-28 速溶解性医薬組成物 Active JP5907945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN742/DEL/2010 2010-03-29
IN742DE2010 2010-03-29
PCT/EP2011/054698 WO2011120903A2 (en) 2010-03-29 2011-03-28 A fast dissolving pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2013523676A JP2013523676A (ja) 2013-06-17
JP2013523676A5 true JP2013523676A5 (enExample) 2014-04-24
JP5907945B2 JP5907945B2 (ja) 2016-04-26

Family

ID=54241475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501779A Active JP5907945B2 (ja) 2010-03-29 2011-03-28 速溶解性医薬組成物

Country Status (23)

Country Link
US (2) US10086078B2 (enExample)
EP (1) EP2552403B1 (enExample)
JP (1) JP5907945B2 (enExample)
KR (1) KR101725173B1 (enExample)
CN (1) CN102821755A (enExample)
AR (1) AR080736A1 (enExample)
AU (1) AU2011234636B2 (enExample)
BR (1) BR112012024428A2 (enExample)
CA (1) CA2793405A1 (enExample)
DK (1) DK2552403T3 (enExample)
ES (1) ES2553568T3 (enExample)
HU (1) HUE026213T2 (enExample)
IL (1) IL222086A (enExample)
JO (1) JO3112B1 (enExample)
MX (1) MX2012011204A (enExample)
NZ (1) NZ602441A (enExample)
PL (1) PL2552403T3 (enExample)
PT (1) PT2552403E (enExample)
RU (1) RU2566270C2 (enExample)
SA (1) SA111320317B1 (enExample)
TW (1) TWI513477B (enExample)
WO (1) WO2011120903A2 (enExample)
ZA (1) ZA201207176B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2712989T3 (es) 2009-10-30 2019-05-17 Ix Biopharma Ltd Forma de dosificación sólida de disolución rápida
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
MX345674B (es) * 2011-09-16 2017-02-10 Ferring Bv Composicion farmaceutica de disolucion rapida.
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
EP3134076A4 (en) * 2014-04-25 2017-12-20 R.P. Scherer Technologies, LLC A stable montelukast solution
KR20190104322A (ko) 2017-01-11 2019-09-09 훼링 비.브이. 속붕해성 약학적 조성물
CN111904936B (zh) * 2020-08-28 2022-07-19 开封康诺药业有限公司 一种法莫替丁冻干粉针剂
WO2022069956A1 (en) 2020-09-29 2022-04-07 Millicent Pharma Limited Orodispersible formulations
EP4243602A4 (en) 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA251629A (en) 1925-07-14 T. Hanna William Coal cutting knife
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
JPS5446841A (en) 1977-08-16 1979-04-13 Wellcome Found Drug substituted hapten substance and production thereof
CN1053808C (zh) 1993-04-24 2000-06-28 章修纲 尼非地平控释剂型
EP0879600A1 (en) 1997-05-20 1998-11-25 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Fructan containing composition for the prevention and treatment of colon cancer
EP0958825A1 (en) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
WO2000025754A2 (en) 1998-11-04 2000-05-11 Mcneil-Ppc, Inc. Solid oral dosage forms containing alginic acid and famotidine
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
EP1202716A1 (en) * 1999-08-17 2002-05-08 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
BR0112417A (pt) 2000-07-13 2003-07-01 Daiichi Seiyaku Co Composições farmacêuticas contendo composto dds
IT1319664B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali.
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
AU2003240759B2 (en) * 2002-04-03 2008-02-14 Solvay Pharmaceuticals B.V. Stabilized natural cannabinoid formulation
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
CA2484724C (en) * 2002-05-07 2007-01-16 Ferring B.V. Pharmaceutical formulations
HUP0400329A3 (en) * 2002-05-27 2005-11-28 Advance Holdings Ltd Dietary supplements from wine vinasses and relevant production process
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
EP1428526A1 (en) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
MXPA05009079A (es) 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
ATE387207T1 (de) 2003-09-05 2008-03-15 Myung-Jun Chung Zweifach coating-beschichteten milchsäurenbakterienpulver mit protein und polysaccharid und das verfahren zur deren herstellung sowie deren dosisform
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US20060088593A1 (en) 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
CN100339081C (zh) * 2004-11-10 2007-09-26 范敏华 一种氯雷他定口腔崩解片剂的制备方法
RU2007127999A (ru) * 2004-12-23 2009-01-27 МакНЕЙЛ-ППС, ИНК. (US) Орально распадающееся фармацевтические композиции с сенсорными сигнальными агентами
US20070042023A1 (en) 2005-08-22 2007-02-22 National Starch And Chemical Investment Holding Corporation Dissolvable film
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
HUE051267T2 (hu) 2005-12-13 2021-03-01 Harvard College Sejttranszplantációs állványok
US20070293582A1 (en) 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
BRPI0809454A2 (pt) 2007-03-27 2014-09-09 Procter & Gamble Métodos e kits para a administração de probióticos
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
KR100930427B1 (ko) 2008-01-25 2009-12-08 정명준 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
JP2012500643A (ja) * 2008-08-28 2012-01-12 セーホーエル.ハンセン アクティーゼルスカブ 細菌組成物
KR101790188B1 (ko) 2010-03-29 2017-10-25 훼링 비.브이. 속용성 약학 조성물
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
MX345674B (es) 2011-09-16 2017-02-10 Ferring Bv Composicion farmaceutica de disolucion rapida.
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release

Similar Documents

Publication Publication Date Title
JP2013523677A5 (enExample)
JP2013523676A5 (enExample)
RU2014105585A (ru) Быстрорастворимая фармацевтическая композиция
RU2012141140A (ru) Быстрорастворимая фармацевтическая композиция
RU2012141141A (ru) Быстрорастворимая фармацевтическая композиция
JP2011201907A5 (enExample)
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
JP2013518107A5 (enExample)
JP2016065086A5 (enExample)
JP2007506775A5 (enExample)
PE20181177A1 (es) Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas
JP2012502037A5 (enExample)
JP2008533007A5 (enExample)
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2016540021A5 (enExample)
JP2016501828A5 (enExample)
JP2015525763A5 (enExample)
JP2013542247A5 (enExample)
JP2014221827A5 (enExample)
PE20130378A1 (es) Formulaciones de apixaban
JP2011527299A5 (enExample)
JP2008505857A5 (enExample)
JP2014218522A5 (enExample)
MY160652A (en) Pharmaceutical composition for oral administration